Clinical trial registry record

Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 19, 2020.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02802657
Last registry update
May 19, 2020
Status
Unknown
Phase
Phase 4
Sponsor
Xiaodong Sun
Enrollment
141
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
141
Population
ALL · 50 Years
Duration
2016-09-01 to 2020-09-01
Intervention
Treat-and-Extend regimen; Pro Re Nata; Conbercept
Comparator
Conbercept 0.5mg Pro Re Nata
Outcomes measured
Mean Snellen BCVA at every visit or treatment — 24 months; Number of participants with treatment-related adverse events — 24 months; Mean number of injections after the initial three loading dose monthly injections — 21 months; mean central macular thickness at every visit or treatment by OCT — 24 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON